


PRODUCT INFORMATION



QLT0267

Item No. 34309

CAS Registry No.: 866409-68-9
Formal Name: 4-((4-methoxyphenyl)diazenyl)-1H-pyrazole-3,5-diamine
MF: C₁₀H₁₂N₆O
FW: 232.2
Purity: ≥98%
UV/Vis.: λ_{max}: 230, 365 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

QLT0267 is supplied as a solid. A stock solution may be made by dissolving the QLT0267 in the solvent of choice, which should be purged with an inert gas. QLT0267 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of QLT0267 in these solvents is approximately 30 mg/ml. QLT0267 is slightly soluble in ethanol.

Description

QLT0267 is an inhibitor of integrin-linked kinase (ILK; IC₅₀ = 26 nM).¹ It is greater than 10-fold selective for ILK over cyclin-dependent kinase 1 (Cdk1), Cdk2, and Cdk5, as well as greater than 1,000-fold selective for ILK over C-terminal Src kinase (CSK), DNA-PK, Pim-1, Akt, PKC, and casein kinase 2 (CK2), at 10 mg/ml. QLT0267 inhibits the growth of NPA187 papillary thyroid cancer cells (IC₅₀ = ~3 μM) and induces apoptosis in NPA187, DRO, and K4 cancer cell lines. *In vivo*, QLT0267 (100 mg/kg) reduces tumor growth in a DRO mouse xenograft model. It also reduces tumor volume and intratumoral blood vessel mass in a U87MG glioblastoma mouse xenograft model.²

References

1. Younes, M.N., Kim, S., Yigitbasi, O.G., *et al.* Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. *Mol. Cancer Ther.* **4(8)**, 1146-1156 (2005).
2. Edwards, L.A., Woo, J., Huxham, L.A., *et al.* Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK). *Mol. Cancer Ther.* **7(1)**, 59-70 (2008).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/11/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM